Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Coherus Oncology reported encouraging interim clinical data from its TREGCHECK development program, showing anti-tumor activity for tagmokitug in combination with toripalimab for solid tumors.
Filed: 2026-10-29 AccNo: 0001104659-26-119912 Size: 1 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Coherus Oncology, Inc. announced it will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference and the Jefferies Global Healthcare Conference in November 2026.